STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pacibekitug, a Novartis antibody targeting IL-6 (interleukin-6), led to sustained decreases in inflammation biomarkers in the Phase 2 TRANQUILITY midstage study.
- Investigators reported a dose-dependent drop in biomarker levels on certain measures, meaning higher doses produced greater reductions — a sign the drug is having an effect.
- Novartis presented the results Saturday at the European Society of Cardiology's annual meeting in Munich, while experts wait to hear how the company plans to advance pacibekitug as a potential cardiovascular treatment.
- Pacibekitug is interleukin-6 (IL-6), a protein involved in regulating immune responses, positioning the drug as an anti-inflammatory approach to cardiovascular disease.
- The drug was newly acquired by Novartis, making the TRANQUILITY results the first major clinical signal under the company's stewardship.
Why it matters: Pacibekitug's dose-dependent biomarker reductions give Novartis its first clinical signal on the drug since acquiring it, but the company has not yet announced whether it will push the IL-6 antibody into Phase 3 cardiovascular trials. Until outcomes data — not just inflammatory markers — are generated, it's unclear whether cutting IL-6-driven inflammation actually translates into fewer heart attacks or strokes.
Ask SkimNews
